Education
About Us
Working with TipRanks
Follow Us
Mannkind Corp. (MNKD)
NASDAQ:MNKD
MNKD Stock Chart & Stats
$2.44
-$0.05(-0.80%)
At close: 4:00 PM EST
$2.44
-$0.05(-0.80%)
Day’s Range― - ―
52-Week Range$2.39 - $6.51
Previous CloseN/A
Volume434.88K
Average Volume (3M)6.87M
Market Cap
$751.77M
Enterprise Value$1.15B
Total Cash (Recent Filing)$171.35M
Total Debt (Recent Filing)$473.38M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
May 13, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding308,100,430
10 Day Avg. Volume6,620,959
30 Day Avg. Volume6,871,116
Financial Highlights & Ratios
PEG Ratio-3.69
Price to Book (P/B)-33.97
Price to Sales (P/S)4.97
P/FCF Ratio126.60
Enterprise Value/Market Cap1.53
Enterprise Value/Revenue3.30
Enterprise Value/Gross Profit4.32
Enterprise Value/Ebitda22.12
Forecast
1Y Price Target
$7.25Price Target Upside197.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$451.35M
Bulls Say, Bears Say
Bulls Say
Labeling And Dosing GuidanceUpdated Afrezza dosing guidance is expected to reduce under‑dosing and improve treatment outcomes, potentially encouraging patients to switch from injections or pumps to inhaled insulin.
Pipeline DiversificationAcquisition of scPharma and development of an inhaled nintedanib dry powder candidate create new potential revenue sources beyond royalty income, lowering reliance on a single stream.
Regulatory ProgressFDA label update and enrollment in a pediatric Afrezza study indicate progress toward pediatric approval, which could expand the inhaled insulin's addressable market.
Bears Say
Partner Competition RiskIntroduction of a soft mist inhaler and an oral prostacyclin from a partner could reduce demand for the Tyvaso dry powder inhaler, threatening future royalty income.
Real‑world Efficacy ConcernsReal‑world reports of poor efficacy linked to under‑dosing may limit Afrezza adoption if dosing guidance and provider training do not fully correct usage.
Royalty And Revenue UncertaintyUncertainty about how competing treatments and future approvals will affect royalty payments creates valuation risk given the company's exposure to partner‑derived royalties.
MannKind News
MNKD FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was $2.39 and its highest was $6.51 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is $751.77M.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is May 13, 2026 which is in 50 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Feb 26, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of $0.017 by -$0.067.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is >-0.01.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 308,100,430 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of -$0.05 in its last earnings report, missing expectations of $0.017. Following the earnings report the stock price went down -7.429%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Currently, no hedge funds are holding shares in MNKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.25 (197.13% Upside)
$7.25 (197.13% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 26.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $259.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.04%
12-Months-Change
Fundamentals
Return on Equity
-11.21%
Trailing 12-Months
Asset Growth
101.14%
Trailing 12-Months
Company Description
Mannkind Corp.
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
MNKD Company Deck
MNKD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue performance driven by Tyvaso DPI and Afrezza, alongside strategic growth initiatives such as the acquisition of scPharmaceuticals. However, challenges such as a decline in VGo revenue and increased SG&A expenses were noted. Overall, the positive aspects of revenue growth and strategic acquisitions outweighed the lowlights.View all MNKD earnings summariesMNKD Stock 12 Month Forecast
Average Price Target
$7.25
▲(197.13% Upside)
Technical Analysis
Ownership Overview
2.98% Insiders
11.25% Mutual Funds
15.17% Other Institutional Investors
55.02% Public Companies and Individual Investors